The Effect of Abraxane on Cell Kinetic Parameters of HeLa Cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4229-4233

  Gurses, Nurcan ^a   Topcul, Mehmet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Abraxane; Cervical cancer; HeLa; In vitro; Nab paclitaxel; Nanodrugs

Indexed keywords

ALBUMIN BOUND PACLITAXEL; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; PACLITAXEL;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; FEMALE; HUMAN; MITOSIS INDEX; PATHOLOGY; TUMOR CELL CULTURE; UTERINE CERVIX TUMOR;

ALBUMINS; APOPTOSIS; CELL PROLIFERATION; FEMALE; HUMANS; MITOTIC INDEX; PACLITAXEL; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84885435718     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4229     Document Type: Article

References (18)

1. Brannon-Peppas L, Blanchette JO (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev, 56, 1649-59.
2. Danhier F, Lecouturier N, Vroman B, et al (2009). Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Controlled Release, 133, 11-7.
3. Demeure MJ, Stephan E, Gonzales P, et al (2008). Pre-clinical evidence for nab-paclitaxel efficacy in the treatment of adrenocortical cancer. J Clin Oncol, 26, 22070.
4. Desai N, Trieu V, Yao Z, et al (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12, 1317-24.
5. Fader AN, Rose PG (2009). Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer, 19, 1281-3.
6. Gradishar WJ, Tjulandin S, Davidson N, et al (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23, 7794-803.
7. Green MR, Manikhas GM, Orlov S, et al (2006). Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol, 17, 1263-8.
8. HTTP://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm 16.05.2013.
9. HTTP://www.has-sante.frportailuploaddocsapplicationpdf2011-01abraxane_ct_7088.pdf 10.02.2013.
10. Kratz F (2008). Albumin as drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Controlled Release, 132, 171-83.
11. Lin LY, Karwa A, Kostelc JG, et al (2012). Paclitaxel-loaded SCK nanoparticles: an investigation of loading capacity and cell killing abilities. In Vitro Mol Pharmaceutics, 9, 2248-55.
12. Saunders DE, Dwayne-Lawrence W, Christensen C, et al (1997). Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer, 70, 214-20.
13. Sparreboom A, Scripture CD, Treiu V, et al (2005). Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound Paclitaxel (ABI-007) and Paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res, 11, 4136-43.
14. Topcul M, Cetin I (2013). Nanotechnology in the field of clinical oncology. Marmara Med J, 26, 1-4.
15. Wiedenmann N, Valdecanas D, Hunter N, et al (2007). One hundred thirty-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res, 13, 1868-74.
16. Yang Y, Niu X, Zhang Q, et al (2010). In vitro inhibiting effect of albumin-bound paclitaxel on human osteosarcoma cell os-732. Shandong Med J, 50, 24-26.
17. Yang Y, Niu X, Zhang Q, et al (2012). The efficacy of Abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J Med Sci, 344, 199-205.
18. Zhang C, Awasthi N, Schwartz MA, et al (2013). Superior antitumor activity of nanoparticle albumin-bound Paclitaxel in experimental gastric cancer. Plos One, 8, 1-10.